This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
CHICAGO, Feb. 20, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that Durata's Chief Executive Officer Paul R. Edick will present an overview of the company at the Cowen & Company Healthcare Conference in Boston, MA. The Durata presentation will take place at The Boston Marriott Copley Place on Wednesday, March 6, 2013 at 9:20 a.m. EST.
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed its DISCOVER 1 study and enrollment in its DISCOVER 2 global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.
The Durata Therapeutics, Inc. logo is available at
Any statements in this press release about Durata's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.
CONTACT: Investor Relations and Public Affairs Contact
Allison Wey - Durata Therapeutics
Vice President, Investor Relations and Public Affairs
(312)219-7017 - firstname.lastname@example.org